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We showed that the migration, morphology and adhesiveness of undifferentiated mesenchymal
cells dramatically changed during osteogenic differentiation. The migration of these cells was tran-
siently upregulated early in osteogenic differentiation. At a later stage, migration was decreased but
adhesiveness was increased. Furthermore, Cdc42 and Rac1 Rho-family small GTPases were activated
at early stages of differentiation and the phosphorylation level of FAK decreased as differentiation
progressed. We also showed cell migration was promoted by inhibition of the Rho-ROCK-myosin
signaling. Finally, using a mouse model of ectopic bone formation, we conﬁrmed that treatment
with ROCK inhibitor, Y-27632 increased cell movement into bone formation sites, resulting in
enhanced osteogenesis. These results provide a new insight into the link between cell migration
and osteogenic differentiation.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction We also reported that signaling of the small GTPase Rho and itsMigration of osteoblast precursor cells is critical for bone forma-
tion and fracture healing [1,2]. In order to form the appropriate
shape of the future bone, both the recruitment and the osteogenic
differentiation of the precursors must be precisely regulated. Cells
originating from the periosteum [3], bone marrow [4,5], circulating
blood [6], and the surrounding soft tissues [7] have been reported to
function as osteoblast precursors. Although a number of individual
studies concerning cell migration and osteogenic differentiation
have been conducted, the precise link between cell migration and
differentiation has not yet been reported.
A number of factors associated with bone have been reported to
induce directional migration of osteoblasts, including transforming
growth factor-b (TGF-b), platelet derived growth factor (PDGF),
insulin-like growth factor (IGF), bone morphogenetic protein
(BMP), and vascular endothelial growth factor (VEGF) [8–12]. We
have also reported chemotaxis of osteoblasts to IGF-1 that is
secreted from the osteoblasts themselves [13]. We thus hypothe-
sized that these soluble factors regulated both prior cell migration
and osteogenic differentiation.chemical Societies. Published by E
focal adhesion kinase; OPN,
sx, osterix; OCN, osteocalcin;
.target ROCK regulates osteogenic differentiation [14]. In that study,
we noticed that inhibition of Rho-ROCK signaling using Y-27632
enhanced bone mass in an ectopic bone formation model through
induction of osteogenic differentiation. However, the effect of the
ROCK inhibitor on precursor cell migration is unclear. Several
studies have shown that ROCK inhibition reduces cell contractility,
actin cytoskeleton assembly and focal adhesion turnover, all of
which result in loss of cell motility [15–17]. In contrast, ROCK inhi-
bitionpromotes themigrationof primary rat embryoﬁbroblasts and
osteosarcoma cells [18–21]. Thus, the effect of ROCK appears to dif-
fer depending on the cell type and the testing system used [22,23].
In this study, we determined if cell migration was altered dur-
ing osteogenic differentiation using mesenchymal cell lines (ST2)
and primary bone marrow derived cells (BMDCs). We also exam-
ined the effect of ROCK inhibition on the migration abilities of
these cells. Our ﬁndings may lead to a new therapeutic strategy
for bone formation and fracture healing.2. Materials and methods
2.1. Osteogenic induction
ST2 cells (7.5  104 cells/dish) were plated in 6-cm dishes (BD
Falcon, Bedford, MA). To induce osteogenic differentiation, the cul-
ture medium was changed from maintenance medium (RPMI1640lsevier B.V. All rights reserved.
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Fig. 1. Osteogenic differentiation affected cell migration ability. (A) Schematic presentation of the experimental protocol of the osteogenic differentiation assay. Osteogenic
differentiation of ST2 cells was induced by treatment with rhBMP-2 (50 ng/ml). The arrows indicate the composition of the culture medium; non-inducing medium, blue;
osteogenic induction medium, red. (B) ALP staining and activity during osteogenic induction over the indicated period (0–3 days) (n = 7). (C) RT-PCR analysis of the mRNA
expression of various osteogenic marker genes. (D) Immunoﬂuorescent staining of the actin cytoskeleton during osteogenic differentiation. Phase contrast images are shown
at the top. (E) Quantiﬁcation of cells with a motile phenotype (n = 5). (F) Quantiﬁcation of cell area after osteogenic induction (n > 100). (G) Cell motility during osteogenic
differentiation assayed using a modiﬁed Boyden chamber assay (n = 6). (H) Wound healing assay of differentiated ST2 cells (n = 5). (I) Assay of cell adhesion during osteogenic
differentiation. (J) Activity of cellular Cdc42, Rac1 and RhoA was analyzed using a pull-down assay of the GTP-bound active forms. Levels of the GTP-bound (GTP) proteins and
total cellular GTPases, were analyzed by Western blotting (top). (K) Western blotting analysis of the phosphorylation level of FAK and MLC, and the ratio of phosphorylated to
non-phosphorylated protein during osteogenic differentiation (n = 4).
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minimal essential medium (a-MEM) (Invitrogen) supplementedwith 10% FBS and 50 ng/ml rhBMP-2), and the cells were then cul-
tured for the indicated period (0–3 days).
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Fig. 2. The ROCK inhibitor, Y-27632, stimulated osteogenic differentiation and cell migration. (A) Schematic outline of the experimental protocol used to examine the effects
of Y-27632 with or without rhBMP-2 on osteogenic differentiation and cell migration. (B) ALP staining and activity after treatment of ST2 cells with rhBMP-2 (BMP-2, 50 ng/
ml) and/or Y-27632 (Y, 10 lM) (n = 5). Con, control. (C) Immunoﬂuorescent staining of the actin cytoskeleton and vinculin (a marker of focal adhesions) after the indicated
treatments. (D) Quantiﬁcation of cells with a motile phenotype (n = 6). (E) Wound healing migration assay of treated cells (see also Supplemental movies 1–4) (n = 4). (F)
Adhesion assay of treated cells. (G) Activity of Cdc42 and Rac1 detected using a pull-down assay of the GTP-bound active forms.
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Fig. 3. Y-27632 and the myosin II inhibitor, blebbistatin, enhanced undifferentiated mesenchymal cell motility. (A) Wound healing migration assay of control ST2 cells (con)
or ST2 cells treated with Y-27632 (Y) or blebbistatin (n = 5). (B) Phase contrast microscopy of passage-4 BMDCs prepared from C57BL/6 mice. (C) Osteogenic differentiation of
BMDCs following treatment with rhBMP-2 (50 ng/ml) was analyzed by staining for ALP (cultured for 3 days) and by alizarin red S staining of calcium deposits (cultured for
15 days). Adipogenic differentiation, induced by treatment with troglitazone (2 lM) for 10 days, was assayed by staining of lipid droplets with Oil Red O. (D) Wound healing
migration assay of control BMDCs (con) or BMDCs treated with Y-27632 (Y) or blebbistatin (n = 4). Treatment with Y-27632 (10 lM) did not enhanced cell motility of (E)
differentiated ST2 cells (on days 3) (n = 6) or (F) MC3T3-E1 cells (n = 8) in a wound healing assay.
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3. Results and discussion
3.1. The motility of progenitor cells dramatically changed during
differentiation
In order to investigate the link between cell migration and
osteogenic differentiation, we compared the migration ability of
four different mesenchymal cell lines with Boyden chamber assay
using FBS as a chemoattractant. These cells were different stages of
differentiation as showing several lineage speciﬁc marker expres-
sions (Supplementary data, Fig. S1A and B). Migration abilities
were varied and undifferentiated cells showed faster migration
ability (Supplementary data, Fig. S1C–F). ST2 cells could differenti-
ate into osteogenic, chondrogenic and adiogenic cells under
appropriate culture conditions (Supplementary data, Fig. S1G),
thus ST2 cells showed the ability of pluripotent undifferentiated
mesenchymal cell. Next, we induced osteogenic differentiation of
ST2 cells using rhBMP-2 is shown in Fig. 1A. Osteogenic differenti-
ation was detected by ALP staining and measurement of ALP
enzyme activity (Fig. 1B). ALP activity was increased after induc-
tion and reached a plateau on day 2 of induction. The expression
of various osteogenic marker genes during differentiation was
analyzed using RT-PCR (Fig. 1C). Some genes, such as Runx2,
OPN, and Col1a1 were continuously expressed throughout the en-
tire experiment. Expression of PTHR and Osx genes was detected
on day 1 after induction and that of the OCN gene on day 2 after
induction. The expression of all three of these genes increased
along with the induction time. Thus, osteogenic differentiation
was gradually induced after rhBMP-2 treatment.
We next analyzed morphological changes in these cells during
differentiation. Using immunoﬂuorescent staining, we analyzed
the actin cytoskeleton and focal adhesion formation (Fig. 1D).Undifferentiated (0 d) cells showed marked actin stress ﬁbers
(red) and numerous focal adhesions (green). These structures were
dramatically attenuated on day 1 of induction, which is indicative
of cells with a motile phenotype, but actin stress ﬁbers and focal
adhesion formation reappeared on days 2 and 3 after induction.
These changes in the motile phenotype of the cells were conﬁrmed
by quantitative analysis (Fig. 1E), and measuring cell area (Fig. 1F).
We then analyzed the migration ability of these cells during induc-
tion of osteogenic differentiation using modiﬁed Boyden chamber
and wound healing assays (Fig. 1G and H). Cell migration was
signiﬁcantly enhanced on day 1 of induction in both assays, but
was decreased to the basal level by day 3 of induction. Conversely,
cell adhesiveness did not change on day 1, but was upregulated on
days 2 and 3 after induction (Fig. 1I). To distinguish whether the
changes of mesenchymal cell migration was caused by rhBMP-2
or by the osteogenic differentiation, we checked the direct effect
of rhBMP-2 on cell migration during short period (Supplementary
data, Fig. S2). rhBMP-2 did not affect cell migration as a chemoat-
tractant. Thus, the cell migration change was caused by osteogenic
differentiation. Lastly, biochemical changes related to cell migra-
tion were examined in these cells. The activity of Cdc42 and Rac1
was signiﬁcantly increased on day 1 of induction, similar to cell
migration (Fig. 1G, H, and J). Then, it was declined the control level
on day 3. By contrast, the change of the activity of RhoA was
marginal during induction. The phosphorylation level of FAK,
which is responsible for focal adhesion turnover, decreased as
differentiation proceeded (Fig. 1K). This down-regulation of the
phosphorylation level of FAK and the resultant decrease in focal
adhesion turnover may account for the enhanced adhesiveness of
the cells at later stages of induction (Fig. 1I). The phosphorylation
level of MLC, related to actomyosin contractility, showed no signif-
icant change during induction. In addition, using video recording of
the cells, we noticed that cell protrusions of individual cells were
markedly enhanced on day 1 of induction (Supplementary movies
3 and 4). Based on these results, we speculated that differentiated
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4022 M. Ichida et al. / FEBS Letters 585 (2011) 4018–4024cells on day 1 were more motile than undifferentiated cells and
move through the activation of Cdc42 and Rac1, which is critical
for mesenchymal mode of migration. The mesenchymal mode of
cell migration has been reported to be enhanced by the inhibition
of Rho-ROCK-myosin signaling [18–21]. We therefore next deter-
mined of the effect of ROCK inhibitor, Y-27632, on ST2 migration.
3.2. A mesenchymal mode of cell migration was promoted by
inhibition of ROCK signaling
The experimental protocol is shown in Fig. 2A. To determine if
the ST2 cells migrated using a mesenchymal mode of migration,
we compared parameters of migration in cells treated with
Y-27632 and/or rhBMP-2 for 1 day. ALP activity was enhanced by
treatment with Y-27632 as well as by rhBMP-2. Treatment with
both rhBMP-2 and Y-27632 resulted in marked high ALP activity
(Fig. 2B). Cell shape was also changed by treatment with
Y-27632 (Fig. 2C and D) and Y-27632-treated cells showed
enhanced cell protrusion compared to rhBMP-2 treated-cells (Sup-
plementary movies 3 and 4). This shape change was accompanied
by attenuation of actin stress ﬁbers and focal adhesion formationsuggesting enhanced cell migration (Fig. 2E). Treatment with both
rhBMP-2 and Y-27632 resulted in morphological changes similar
to those observed following Y-27632 treatment alone. Cell migra-
tion in the wound healing assay was enhanced by treatment with
Y-27632 as well as with rhBMP-2, but an additive effect of Y-27632
was not detected (Fig. 2E). We speculated migration speed of ST-2
was maximized at the BMP-2 treatment with/without Y-27632. By
contrast, ALP activity was increased when we used rhBMP-2 with
Y-27632. Y-27632 treatment stimulated the production of endog-
enous murine BMP-4 in ST2 cells (Supplementary data, Fig. S3).
We also found that ALP activity reached a plateau even increasing
amount of only rhBMP-2 (Supplementary data, Fig. S4). We specu-
lated that Y-27632 induced osteogenic differentiation not only by
increased BMP production but also by unknown additional mech-
anism. Thus, the combined treatment showed additive effect for
ALP activity in ST2 cells (Fig. 2B). Cell adhesiveness was decreased
by treatment with Y-27632 and with both rhBMP-2 and Y-27632,
but not with rhBMP-2 alone (Fig. 2F). Finally, the activity of
Cdc42 and Rac1 was not changed following treatment with
Y-27632 but it was signiﬁcantly increased by treatment with
rhBMP-2 (Fig. 2G). These data indicated that adhesiveness and cell
M. Ichida et al. / FEBS Letters 585 (2011) 4018–4024 4023morphology during osteogenic induction were different between
Y-27632-treated and rhBMP-2-treated cells. These differences
may reﬂect different mechanisms by which these treatments
induce a mesenchymal mode of cell migration. Thus, while the
rhBMP-2-treated cells did not modulate cells adhesion, these cells
showed enhanced cell rufﬂing as well as cell protrusion compared
to controls (Supplementary movies 1–4), which is the characteris-
tic shape of mesenchymal mode migrating cells. In contrast, the
Y-27632-treated cells showed decreased cell adhesion and
enhanced cell protrusion compared to the rhBMP-2-treated cells.
These results suggested that treatment with Y-27632 induced a
mesenchymal mode of cell migration by inducing a decrease in cell
adhesiveness.
We further examined the role of RhoA signaling in the mesen-
chymal mode migration of the cells by inhibition of the Rho-
ROCK-myosin signal using blebbistatin, a speciﬁc myosin ATPase
inhibitor. The proliferation of ST2 cells was not changed by treat-
ment with either Y-27632 (10 lM) or blebbistatin (10 lM) (data
not shown). Wound healing was accelerated by treatment with
either Y-27632 or blebbistatin (Fig. 3A). The phosphorylation level
of MLC decreased following treatment with Y-27632, but was not
changed by blebbistatin treatment. We also found ALP activity
was not increased by treatment with blebbistatin (Supplementary
data, Fig. S5). Thus, we speculated that the inhibition of Rho-ROCK-
myosin signaling with blebbistatin increased cell migration
without osteogenic induction. On other hand, inhibition of ROCK
with Y-27632 enhanced both osteogenic induction and cell migra-
tion in undifferentiated cells. To further analyze the effects of
Y-27632 and blebbistatin on mesenchymal cell migration, we pre-
pared primary mouse mesenchymal cells from bone marrow and
expanded these BMDCs in vitro. These cells showed the character-
istic spindle-shape of mesenchymal stem cells on the plastic
culture dish (Fig. 3B) and could differentiate into osteoblasts or
adipocytes under the appropriate culture conditions (Fig. 3C).
Treatment with either Y-27632 or blebbistatin increased wound
healing of primary BMDCs (Fig. 3D). These results indicated that
inhibition of ROCK signaling that is downstream of RhoA, induced
increased migration, not only of ST2 cells, but also of BMDCs. In
order to evaluate whether Y-27632 promoted migration of undif-
ferentiated or differentiated mesenchymal cells, we examined
whether Y-27632 promote migration of differentiated ST2 cells
and MC3T3-E1 preosteoblast cell line in vitro. Y-27632 did not
promote cell migration of differentiated cells (Fig. 3E and F). Thus,
we speculated that the effect of Y-27632 is speciﬁc to undifferen-
tiated cells.
3.3. Upregulated migration of progenitor cells increased ectopic bone
formation
We lastly investigated the effect of Y-27632 and rhBMP-2
treatment on cell migration and bone formation in vivo. We im-
planted a rhBMP-2-collagen1 composite into a dorsal subfascial
pocket and observed ectopic bone formation. For analysis of the
effect of Y-27632, this inhibitor was continuously released from an
osmotic pump (Fig. 4A). Using HE staining and in situ hybridization,
recruitment of osteopontin positive cells into the rhBMP-2-colla-
gen1 composite was observed, 4 days after implantation in
Y-27632-treated mice, but not in control mice (Fig. 4B). We also
observed bigger calciﬁed ossicles over a period of 1 week in the
Y-27632-treated group compared to the control group, using HE
staining of histological sections of the BMPcomposite (Fig. 4C),mac-
roscopic imaging of ectopic ossicles (Fig. 4D) and radiographic anal-
ysis of the ossicles (Fig. 4E). These results suggested that the
migration ability of undifferentiatedmesenchymal cells was upreg-
ulated by in vivo treatment with Y-27632 and resulted in enhanced
bone formation.In summary, we propose a hypothetical model to explain the
ﬁndings of this study (Fig. 4F). Firstly, when progenitor cells
receive an osteogenic differentiation signal such as BMP-2, cell
morphology changes over time and cell motility is temporary
enhanced via activation of both Cdc42 and Rac1. Subsequently,
motility gradually decreases, day by day, following differentiation.
At a later stage, the differentiated cells have low motility and high
adhesion ability via the low turnover of focal adhesion. Thus, cell
migration dramatically changes at each stage of differentiation.
We speculated that inhibition of Rho-ROCK-myosin signaling
leaded to make a change of balance between Cdc42/Rac1 and RhoA
activity, which induced a mesenchymal mode of cell migration.
Further study is necessary to investigate the precise factors that
control these phenomena. Elucidation of the link between migra-
tion and differentiation could provide useful future clinical appli-
cations for bone formation, fracture healing, and regenerative
medicine.Acknowledgements
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